Next Generation Sequencing Market Size By Product Type (Instruments, Consumables, Services), By Application (Research Application, Clinical Application {Cardiovascular, Reproductive Health, Cancer, Infectious Diseases}, Other Applications), By Type (Whole

Next Generation Sequencing Market will exceed USD 15 billion by 2025; as per a new research report.

Introduction of rapid and advanced sequencing technologies and its extensive usage in analyzing DNA will propel next generation sequencing market growth. NGS technology has transformed the method of gene mapping, data interpretation and analysis of large genome bases that aid the researchers and scientists to develop drugs for several diseases. For instance, NGS is used in pathogen detection that proves to be an alternative method used in characterization of unwanted pathogens in clinical specimen. Thus, high usage of NGS instruments in developing drugs that will foster market growth throughout the forecast timeframe.

Increasing use of NGS technology by pharmaceutical and biopharmaceutical companies in advanced economies will foster the market growth in the upcoming timeframe. Leading NGS platform companies such as Life technologies and Illumina have made claims that whole genome can be sequenced for USD 1000 and further predicted that its price will decline over coming years. Thus, growing use of NGS technology coupled with constant decline in prices will foster the industry growth. However, currently the price of NGS instruments are high that may hamper its demand in developing and under developed countries. This may have a short term negative impact on the industry growth.

Instrument segment will experience 20% growth throughout the forecast period. Segment growth is attributed to the availability of technologically upgraded NGS instruments that enables scientists and researchers to carry out drug discovery activities efficiently. Recently developed NGS instruments also help in reducing the capital cost required for research processes drastically. For instance, Illumina launched Novaseq in 2017 that is Illimina’s latest high-output instrument. This instrument has helped in sequencing large databases with minimum costs. Availability of such NGS instruments should surge the segment growth.

Research application segment held around 40% revenue share in 2018. Commendable segment growth will be as a result of growing prevalence of rare genetic diseases that have forced the researchers to develop novel gene therapies. NGS consumables and instruments have been explicitly utilized to sequence the genome for understanding the nature of disease. Hence, high adoption of NGS instruments that facilitate the research process should have positive impact on segment growth.

Exome sequencing segment was valued at 1.8 billion in 2018 and is expected to witness robust growth over the coming years. Segmental growth is associated with the high preference by doctors and researchers for analyzing genome sequence. Exome sequencing typically allows identification of specific protein coding regions of gene that enhances specificity of the sequencing process. Aforementioned factors are projected to drive segmental growth.

Pharmaceutical and biotechnology companies segment will have around 21% growth throughout the forecast timeframe. These companies are actively involved in R&D activities for developing drugs for several chronic conditions. To manufacture commercially viable and reliable drugs, these companies adopt technologically advanced NGS instruments that should escalate the segmental growth.

North America next generation sequencing market is expected to experience 20.3% growth throughout the analysis period. Positive regulatory scenario and trade policies should surge the industry growth. Furthermore, majority of the research processes for drug discovery are carried out in the U.S. and well-equipped laboratories facilitate research processes. Also, the governments funds and supports these research activities that will foster adoption of NGS instruments thereby, triggering regional market growth.

Prominent industry players operational in the next generation sequencing market include 10X Genomics, Agilent, BGI, Bio-Rad, Genapsys, Illumina, Long Read Solutions, Nanostring, Oxford Nanopore, Pac-Bio, Qiagen, Roche, Thermofisher. Strategies adopted by these players are collaboration and agreement, partnership and new product launch. For instance, in January 2017, Illumina launched Novaseq instrument that is integrated with advanced technology. Introduction of new products will enhance company’s revenue generation.